In the Dmp1-null mouse model of ARHR, genetic overexpression of a Dmp1 transgene fully rescues FGF23 levels, hypophosphatemia, and bone defects (21, 34–36), but studies specifically targeting FGF23 in models of ARHR are scarce. Here, DMP1 is linked to hypophosphatemia.